Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide | Zendy

Dominic Pilon | Zendy; Ajay S. Behl | Zendy; Lorie Ellis | Zendy; Bruno Émond | Zendy; Patrick Lefèbvre | Zendy; Nancy A. Dawson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide

Author(s) -

Dominic Pilon,

Ajay S. Behl,

Lorie Ellis,

Bruno Émond,

Patrick Lefèbvre,

Nancy A. Dawson

Publication year - 2016

Publication title -

journal of managed care and specialty pharmacy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.126

H-Index - 63

eISSN - 2376-1032

pISSN - 2376-0540

DOI - 10.18553/jmcp.2016.16233

Subject(s) - abiraterone acetate , enzalutamide , medicine , prostate cancer , hazard ratio , proportional hazards model , oncology , docetaxel , cancer , urology , gynecology , androgen deprivation therapy , confidence interval , androgen receptor

Abiraterone acetate (AA) and enzalutamide (ENZ) are oral therapies offering survival benefit to metastatic castration-resistant prostate cancer (mCRPC) patients. Despite the availability of multiple treatment options for mCRPC, there is a lack of information on the effect that being initiated on AA or ENZ has on the combined prostate cancer treatment duration.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research